Processa Pharmaceuticals Inc (PCSA)

$PCSA 💹

pcsa...........................................................................p/m

I like this one alot.. massive potential 10x to 30x

PCSA......................................................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

June 17, 2025

https://ih.advfn.com/stock-market/NASDAQ/processa-pharmaceuticals-PCSA/stock-news/96258390/processa-pharmaceuticals-signs-binding-term-sheet

$PCSA

PCSA............................................................................................p/m

PCSA.........................................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

Moving up 💹

GLTA $PCSA

PCSA let the run commence here

#PROCESSAPHARMACEUTICALS - PURCHASE PRICE PER SHARE $0.615 FOR INSTITUTIONAL INVESTORS, $0.7975 FOR CEO AND BOARD

If results for their metastatic breast, cancer treatment is favorable, could be a 5 to 10 X

insiders and institutions paid three times the price

$PCSA ➡️ $.2530

PCSA...........................https://stockcharts.com/h-sc/ui?s=pcsa&p=W&b=5&g=0&id=p86431144783

PCSA in on the dip here

$PCSA Insider Trading Activity

$PCSA insiders have traded $PCSA stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $PCSA stock by insiders over the last 6 months:

DAVID YOUNG (Pres. Research & Development) purchased 124,500 shares for an estimated $99,288
GEORGE K NG (Chief Executive Officer) purchased 87,200 shares for an estimated $69,542
PATRICK LIN (Chief Business - Strategy Off) purchased 43,500 shares for an estimated $34,691
JUSTIN W YORKE purchased 12,400 shares for an estimated $9,889

$PCSA

Pcsa,bought .2749,just hit zero borrow/103% fee(no rebate)not optionable,charting up,has vol,5m float,earnings surprise 9%,80%insiders,eps up 76%,has cash .23 per share (offering Jan 30) debt/equity.04 green ,volatility is 40% so should be a good flipper if nothing else from this price

Volume spike premarket

PCSA............................................................a/h

pcsa..................................https://stockcharts.com/h-sc/ui?s=pcsa&p=W&b=5&g=0&id=p86431144783

PCSA.........................................................p/m

PCSA.....................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

One year later joy strikes when it only hits .79 + 31% lol

PCSA.....................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

BB PAVM > LCUD MHO

PCSA............................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA............................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA BLOWING UP

PCSA............................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA BIO BEAST COMING IN

PCSA..........................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA...$1.74...on strong news...🥳

PCSA new 52= week low

PCSA new 52=week low

PCSA.................................https://stockcharts.com/h-sc/ui?s=PCSAp=W&b=5&g=0&id=p86431144783

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

News is excellent but with a $50 million shelf and the way they alienated retail with the reverse split and immediate offering they are getting a very limited response to what should be gangbuster news

HANOVER, MD., June 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial which defined the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose Range (RP2DR) for Next Generation Capecitabine (NGC-Cap) administered to patients with Stage III or IV gastrointestinal tract (GI) cancer.

“We are encouraged by the preliminary efficacy analysis from our NGC-Cap Phase 1b dose-escalating safety/tolerability trial demonstrating some anti-tumor activity in patients with advanced GI cancer who have progressive cancer after relapsing or not responding to prior therapy. The favorable response is likely due to NGC-Cap’s ability to distribute more 5-FU to cancer cells than monotherapy capecitabine. The promising Phase 1b safety and tolerability profile plus these early efficacy signals provide validation for further development of NGC-Cap,” stated David Young, PharmD, Ph.D., President of Research and Development at Processa. “From this Phase 1b trial, we have been able to define the MTD and the RP2DR to use in our Phase 2 Optimal Dosage Regimen trial in breast cancer in the third quarter of 2024.”

Dr. Young added, “Given the need for more effective chemotherapy treatment with improved tolerability across multiple types of cancer, we believe that NGC-Cap has the potential to provide a safer, more efficacious option to treat the different cancers for which capecitabine and 5-FU are presently used.”

The NGC-Cap Phase 1b trial is evaluating ascending doses of capecitabine when administered after a single dose of PCS6422 in Stage III or IV patients with advanced, relapsed or refractory progressive GI cancer. All patients relapsed from or failed all other treatments, including prior treatment with capecitabine or 5-FU. For all doses of capecitabine in the Phase 1b NGC-Cap trial, exposure to 5-FU was greater and exposure to FBAL was lower with a better or similar side effect profile compared with monotherapy capecitabine. In addition, preliminary analysis of the efficacy data demonstrated early evidence of anti-tumor activity of capecitabine combined with PCS6422, which was assessed using RECIST 1.1 evaluations (Response Evaluation Criteria in Solid Tumors) by scans every eight weeks.

50m shelf. Company is run by morons. Short it

nice chart

No 1 on the Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

PCSA under $3

https://www.secform4.com/insider-trading/1533743.htm
More insider buying

I love retarded posts like this.

LOL.. this is total garbage. Going under a dollar and then will reverse split again to eliminate current stock holders and start all over.

bullish
$PCSA Bottom chart 2.6M float Offering closed yesterday
Recent r/s name with 3 Insider buys this week and upcoming catalyst pic.twitter.com/QZjt346W0f— STOCKS Gambino (@StocksGambino) February 2, 2024

OFFERING CLOSED... STILL NO MOVEMENT PRESS RELEASE OUT 1 HOUR AGO.

Form 4 insider buys just hit.

Offering now closed-8k

Gonna get interesting when/if we get the filing that the offering is done

Curling up off the lows

please post the spectacular chart, so we can all see